-transparent.png){kind=logo}
Thirty patients with classical or definite rheumatoid arthritis were treated over a 4-week period with diftalone, a new non-steroidal antirheumatic drug. The daily dosage ranged from 500 to 1000 mg. A good objective response was achieved in 69% of the patients. Diftalone was well tolerated. Side effects were noted in 11.8% of patients on 500 mg diftalone daily and in 18.8% of cases treated with the highest dosage (1000 mg daily). The optimum daily dosage appears to be 750 mg.
Related Publications
O Frank, and
M Klicpera, and
G Kolarz, and
O Scherak
September 1981,
MMW, Munchener medizinische Wochenschrift,
O Frank, and
M Klicpera, and
G Kolarz, and
O Scherak
September 1977,
ZFA. Zeitschrift fur Allgemeinmedizin,
O Frank, and
M Klicpera, and
G Kolarz, and
O Scherak
January 1981,
European journal of rheumatology and inflammation,
O Frank, and
M Klicpera, and
G Kolarz, and
O Scherak
October 1977,
Nihon yakurigaku zasshi. Folia pharmacologica Japonica,
O Frank, and
M Klicpera, and
G Kolarz, and
O Scherak
May 1981,
Nihon yakurigaku zasshi. Folia pharmacologica Japonica,
O Frank, and
M Klicpera, and
G Kolarz, and
O Scherak
November 1980,
Ceskoslovenska farmacie,
O Frank, and
M Klicpera, and
G Kolarz, and
O Scherak
May 1954,
Journal de medecine de Bordeaux et du Sud-Ouest,
O Frank, and
M Klicpera, and
G Kolarz, and
O Scherak
January 1984,
Reumatizam,
O Frank, and
M Klicpera, and
G Kolarz, and
O Scherak
November 1979,
ZFA. Zeitschrift fur Allgemeinmedizin,
O Frank, and
M Klicpera, and
G Kolarz, and
O Scherak
January 1991,
Zeitschrift fur Rheumatologie,
